Toronto, Ontario--(Newsfile Corp. - January 30, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle-free subcutaneous drug-delivery technology, announces that Veronique Laberge has resigned from her position as Chief Financial Officer and Corporate Secretary. Her resignation is effective January 31, 2026.The Company has appointed Mr. Ajay Mishra as Chief Financial Officer and Corporate Secretary, effective January 31, 2026. Mr. Mishra will assume responsibility fo ...

Core Viewpoint - Investors are optimistic about the future of AI stocks, driven by the expectation that AI will increasingly integrate into various aspects of life, including surgery [1] Group 1: AI Surgery Opportunities - AI technology is being utilized to assist human doctors in surgical procedures, indicating a growing trend in AI surgery [2] - Intuitive Surgical is a leading company focused solely on surgical robotics, with a significant increase in the installation of its da Vinci surgical robots, from 1,526 in 2024 to 1,721 in 2025, representing a nearly 13% increase [3] - The total number of da Vinci surgical robots in operation reached 11,106 by the end of 2025, marking a 12% year-over-year increase [3] Group 2: Demand and Growth Projections - The demand for surgical robots is strong, with surgeries performed using the da Vinci system increasing by 18% year-over-year in 2025, and an expected rise of up to 15% in 2026 [4] - The FDA has approved an AI tool to assist surgeons in making real-time adjustments during lung surgeries, showcasing the integration of AI in surgical practices [4] Group 3: Investment Considerations - Intuitive Surgical presents a high-risk, high-reward opportunity for aggressive growth investors, despite its high valuation with a price-to-earnings (P/E) ratio of 67 [5] - Medtronic offers a more diversified investment option with a lower P/E ratio of 27, although it is set to spin off its diabetes division soon [6]

Haemonetics Corporation (NYSE:HAE) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds. On January 12, Michael Petusky from Barrington maintained his Outperform rating on Haemonetics Corporation (NYSE:HAE). He also revised his estimated price target upward from $90 to $93, implying an upside of almost 41%. Easiest Md/PhD Programs to Get Into oatautta/Shutterstock.com Petusky’s rating and target price adjustment came at the back of the company’s recent acquisition of Vivas ...

Company Overview - LivaNova PLC (NASDAQ:LIVN) is a medical technology company specializing in cardiovascular and neuromodulation solutions, including heart-lung machines, oxygenators, and VNS therapy systems [4] Analyst Ratings - KeyBanc Capital Markets analyst Brett Fishbin upgraded LivaNova's rating from Sector Weight to Overweight, setting a target price of $81, indicating an upside potential of nearly 27% [1] - Goldman Sachs analyst David Roman maintained a Neutral rating on LivaNova but raised the price target from $56 to $66, expecting valuations to align more closely with fundamentals by 2026 [3] Market Trends - KeyBanc's outlook for the Medical Technology segment in 2026 suggests sustainable underlying trends and a diminished valuation premium, creating favorable conditions for stock picking [2]

Core Insights - iRhythm Holdings (NASDAQ: IRTC) is recognized as one of the top 12 Medical Devices stocks favored by hedge funds [1] - Morgan Stanley maintains an Overweight rating on iRhythm Holdings with a price target of $205, indicating a 35% upside potential from current levels [1] - The company reported preliminary fourth-quarter revenues of approximately $207 million, exceeding consensus estimates of $200 million [2] - iRhythm's 2026 revenue guidance projects a midpoint of around $875 million, excluding contributions from its next-generation Mobile Cardiac Telemetry (MCT) device [2] - Vijay Kumar from Evercore ISI upgraded his rating for iRhythm Holdings to Outperform, raising the price target from $194 to $210, suggesting an upside potential of over 38% [3] - iRhythm Holdings specializes in digital healthcare, focusing on device-based Zio biosensor technology for diagnosing cardiac arrhythmias, and offers both long-term and short-term cardiac monitoring services [4] Company Overview - iRhythm Holdings develops and commercializes Zio biosensor technology for cardiac arrhythmia diagnosis [4] - The company provides mobile cardiac telemetry monitoring and incorporates AI-based data analytics into its operations [4]

Bruker Corporation (NASDAQ:BRKR) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds. On January 26, Guggenheim analyst Subbu Nambi reiterated her Buy rating on Bruker Corporation (NASDAQ:BRKR). She revised her price target from $53 to $58, which leads to an upside potential of almost 25%. Copyright: dolgachov / 123RF Stock Photo Nambi’s target price adjustment is part of Guggenheim’s revisions to its forecasts and targets for many of the stocks within the Diagnostics and ...

Group 1 - Insulet Corporation (NASDAQ:PODD) is recognized as one of the top 12 Medical Devices stocks favored by hedge funds, with a highly bullish consensus view from analysts [1] - The stock has received coverage from 18 analysts, resulting in 16 Buy ratings, 1 Hold rating, and only 1 Sell rating, indicating strong market confidence [1] - The consensus 1-year median price target for Insulet is $369.59, suggesting an upside potential of over 43% from its current level [1] Group 2 - Analyst David Roman from Goldman Sachs reaffirmed a Buy rating for Insulet, adjusting the price target from $388 to $365, while still projecting over 41% upside potential [2] - Roman noted that share price movements in 2025 diverged from company fundamentals, but expects valuations to align closely with organic growth prospects in the coming year [2] Group 3 - Insulet Corporation specializes in manufacturing and selling insulin management systems, particularly through its Omnipod platform, which includes a disposable tubeless pump designed for insulin-dependent diabetes [3] - The company's strategy focuses on high-volume automated manufacturing in the US and Malaysia, along with contract manufacturing in China [3]

Group 1 - GE HealthCare Technologies (NASDAQ:GEHC) is recognized as one of the top 12 Medical Devices stocks to invest in according to hedge funds [1] - David Roman from Goldman Sachs has reiterated a Buy rating for GE HealthCare Technologies and raised the price target from $86 to $98, indicating a potential upside of nearly 24% for investors [1] - Vijay Kumar of Evercore ISI has maintained an Outperform rating on GE HealthCare Technologies, with an upward revision of the price target from $92 to $95, suggesting an anticipated upside of nearly 20% [3] Group 2 - The company operates in the pharmaceutical diagnostics and medical technology sectors, focusing on precision care through the development and marketing of products and services used in patient diagnosis, treatment, and monitoring [5] - GE HealthCare Technologies is structured into four segments: Advanced Visualization Solutions (AVS), Imaging, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx) [5] - Kumar expects 2026 to present interesting prospects for the medical technology space, driven by strong capital expenditure trends and recovery indicators in China [4]

Group 1 - Stryker Corporation (NYSE:SYK) is recognized as one of the top 12 Medical Devices stocks to invest in according to Hedge Funds [1] - Matthew O'Brien from Piper Sandler has reiterated an Overweight rating on Stryker with a price target of $420, indicating over 17% upside potential for investors [1][2] - The company is introducing a new handheld orthopedic robot, Mako RPS, which is expected to enhance its market presence in lower-cost segments, including ambulatory surgical centers and select international markets [2] Group 2 - Evercore ISI has maintained an Outperform rating on Stryker while adjusting the target price from $405 to $390, citing recoveries in end markets and anticipated healthy capital expenditures in the medical technology sector for 2026 [3] - Stryker operates in two segments: MedSurg & Neurotechnology and Orthopaedic, focusing on innovative products to improve patient outcomes [4]

Boston Scientific Corporation (NYSE:BSX) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds. On January 16, Richard Newitter from Truist Securities reiterated his Buy rating on Boston Scientific Corporation (NYSE:BSX). He set a price target of $120, implying almost 28% upside. Polen Capital Bets on Robotic Surgery Leader Intuitive Surgical (ISRG) for Future Growth Copyright: nimon / 123RF Stock Photo The analyst attributed his rating to the company’s strategic acquisitio ...